

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BeOne Medicines Ltd.**

**百濟神州有限公司**

*(a corporation incorporated under the laws of Switzerland)*

**(Stock Code: 06160)**

## **DIRECTOR NOMINEES AND PROPOSED CHANGES IN BOARD COMMITTEE COMPOSITION**

### **DIRECTOR NOMINEES AT THE 2026 ANNUAL GENERAL MEETING**

BeOne Medicines Ltd. (the “**Company**”) announces that based on the recommendation of the nominating and corporate governance committee (the “**Nominating and Corporate Governance Committee**”) of the board (the “**Board**”) of directors (the “**Directors**”) of the Company, the Board nominates the following persons to stand for election by the shareholders of the Company (the “**Shareholders**”) at the forthcoming 2026 annual general meeting of the Company (the “**2026 AGM**”): Dr. Felix J. Baker (“**Dr. Baker**”), Dr. Olivier Brandicourt (“**Dr. Brandicourt**”), Dr. Margaret Han Dugan (“**Dr. Dugan**”), Mr. Anthony C. Hooper (“**Mr. Hooper**”), Ms. Elizabeth F. Mooney (“**Ms. Mooney**”), Mr. John V. Oyler, Dr. Alessandro Riva (“**Dr. Riva**”), Dr. Charles L. Sawyers (“**Dr. Sawyers**”), Ms. Shalini Sharp (“**Ms. Sharp**”) and Dr. Xiaodong Wang (“**Dr. Wang**”). If elected, each nominee will serve as a Director until the completion of the annual general meeting of shareholders in 2027, subject to his or her earlier resignation or removal.

### **NEW DIRECTOR NOMINEES**

Among the ten Director nominees, Dr. Baker, Ms. Mooney and Dr. Sawyers are new director nominees (the “**New Director Nominees**”) who did not previously serve on the Company’s Board. The Board nominates Dr. Baker to serve as a non-executive Director and Ms. Mooney and Dr. Sawyers as independent non-executive Directors.

The biographical information of each of the New Director Nominees and other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) is set forth in the appendix to this announcement.

Except as disclosed in this announcement and as of the date of this announcement, each of the New Director Nominees does not (i) hold any other position with the Company or its subsidiaries; (ii) hold any other directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or other major appointments and professional qualifications; (iii) have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; or (iv) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

Ms. Mooney and Dr. Sawyers (as proposed independent non-executive Directors) have confirmed (i) their independence as regards to each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that they have no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as such term is defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect their independence at the time of their respective appointment.

Except as disclosed in this announcement, there is no information that should be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules and there are no other matters concerning their appointment that need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

A circular containing, among other things, details of the New Director Nominees and other Director nominees, together with a notice of the 2026 AGM will be published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company (<https://beonemedicines.com/>) and despatched to the Shareholders who request the printed copies in due course.

## **DIRECTORS NOT STANDING FOR RE-ELECTION**

Four independent non-executive Directors, namely Mr. Michael Goller (“**Mr. Goller**”), Mr. Ranjeev Krishana (“**Mr. Krishana**”), Dr. Corazon (Corsee) D. Sanders (“**Dr. Sanders**”) and Mr. Qingqing Yi (“**Mr. Yi**”) (collectively, the “**Retiring INEDs**”) will not stand for re-election at the 2026 AGM, and their respective term will expire on the date of the 2026 AGM. With effect from the Retiring INEDs’ retirement at the conclusion of the 2026 AGM, they will cease to serve on the respective Board committees as further described below.

After retirement from all offices with the Company, the Retiring INEDs would devote more time to their other business commitments. The retirement of the Retiring INEDs was not as the result of any disagreement with respect to the operations, policies, or practices of the Company. There is no matter in respect of the Retiring INEDs’ retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Company would like to take this opportunity to express its sincere gratitude to Mr. Goller, Mr. Krishana, Dr. Sanders and Mr. Yi for their exemplary services and invaluable contributions to the Company during their tenure of office.

## **PROPOSED CHANGES IN BOARD COMMITTEE COMPOSITION**

Subject to the election of the ten Director nominees by the Shareholders at the 2026 AGM, the following changes will be made to the Board committees:

- (i) The audit committee (the “**Audit Committee**”) of the Board will consist of Dr. Brandicourt, Mr. Hooper, Ms. Mooney and Ms. Sharp, with Ms. Sharp serving as chair. Dr. Sanders will cease to serve as a member of the Audit Committee.
- (ii) The compensation committee (the “**Compensation Committee**”) of the Board will consist of Dr. Dugan and Ms. Mooney, with Ms. Mooney serving as chair. Mr. Krishana and Mr. Yi will cease to serve as members of the Compensation Committee. Dr. Dugan will cease to serve as chair of the Compensation Committee but will continue to serve as a Director and member of the Compensation Committee and Scientific Advisory Committee.

- (iii) The Nominating and Corporate Governance Committee will consist of Mr. Hooper, Dr. Riva, Dr. Sawyers and Ms. Sharp, with Mr. Hooper serving as chair. Mr. Goller will cease to serve as a member of the Nominating and Corporate Governance Committee.
- (iv) The scientific advisory committee (the “**Scientific Advisory Committee**”) of the Board will consist of Dr. Dugan, Dr. Riva, Dr. Sawyers and Dr. Wang, with Dr. Sawyers and Dr. Wang serving as co-chairs. Mr. Goller, Dr. Sanders and Mr. Yi will cease to serve as members of the Scientific Advisory Committee. Dr. Riva will cease to serve as co-chair of the Scientific Advisory Committee but will continue to serve as a Director and member of the Scientific Advisory Committee and the Nominating and Corporate Governance Committee.
- (v) The commercial and medical affairs advisory committee (the “**Commercial and Medical Affairs Advisory Committee**”) of the Board will consist of Dr. Brandicourt and Mr. Hooper, with Mr. Hooper serving as chair. Mr. Krishana and Dr. Sanders will cease to serve as members of the Commercial and Medical Affairs Advisory Committee. Dr. Dugan will cease to serve as a member of the Commercial and Medical Affairs Advisory Committee but will continue to serve as a Director and member of the Compensation Committee and the Scientific Advisory Committee.

An updated list of directors and their role and function will be published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company (<https://beonemedicines.com/>) following the 2026 AGM.

By order of the Board  
**BeOne Medicines Ltd.**  
**Mr. John V. Oyler**  
*Chairman*

Hong Kong, April 17, 2026

*As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.*

## Appendix

### Non-executive Director

**Dr. Baker**, aged 57, is a managing member of Baker Bros. Advisors LP, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. He also serves on the boards of Kiniksa Pharmaceuticals International, plc, a Nasdaq-listed (ticker symbol: KNSA) biopharmaceutical company; Kymera Therapeutics, Inc., a Nasdaq-listed (ticker symbol: KYMR) clinical stage biopharmaceutical company; Kodiak Sciences Inc., a Nasdaq-listed (ticker symbol: KOD) precommercial retina-focused biotechnology company; and Bicycle Therapeutics plc, a Nasdaq-listed (ticker symbol: BCYC) pharmaceutical company. In the past three years, he served on the board of Seagen, Inc. from July 2003 through December 2023, and IGM Biosciences from 2021 through 2025. Dr. Baker holds a B.S. (1991) and a Ph.D. in Immunology (1998) from Stanford University, where he also completed two years of medical school.

As of the date of this announcement, Dr. Baker is deemed to be interested in 115,918,313 shares of the Company for the purposes of the SFO, representing approximately 7.52% of the issued shares (excluding treasury shares) of the Company.

There will be no service contract between the Company and Dr. Baker. Subject to his election by the Shareholders at the 2026 AGM, Dr. Baker will be entitled to an annual cash compensation of US\$65,000 for his service as a Director and additional cash compensation for serving on any committees of the Board in accordance with the Company's Independent Non-Executive Director Compensation Policy (as amended from time to time, the "**Policy**")<sup>1</sup>. Additionally, Dr. Baker will be entitled to future cash compensation and annual equity grants in accordance with the Policy and the 2016 Share Option and Incentive Plan (as amended from time to time, the "**2016 Plan**").

We believe that Dr. Baker's extensive experience in the biotechnology industry and experience working with and serving on the board of directors of numerous biotechnology and pharmaceutical companies qualifies him to serve on the Board.

### Independent Non-executive Directors

**Ms. Mooney**, aged 57, has over 30 years of experience as a financial expert across many industries. She has decades of experience analyzing businesses through expansion, and taking a long-term perspective to board governance focused on resilience and profitability and bringing value to shareholders and stakeholders. Ms. Mooney was a Partner with Capital Strategy Research of the Capital Group Companies from February 2004 to November 2024. Prior to joining Capital, she served as an equity analyst and a portfolio manager of RCM Capital Management LLC (now VOYA Financial, Inc.) from September 1994 to January 2004. Ms. Mooney is a Certified Public Accountant licensed in Illinois, a Chartered Financial Analyst and a Qualified Risk Director designated by the DCRO Institute. Ms. Mooney received a B.A. degree in economics from The University of Michigan in 1991 and an M.S. in accountancy from DePaul University in 1993.

---

<sup>1</sup> Dr. Baker meets the general independence requirements under Nasdaq Rule 5605(a)(2).

There will be no service contract between the Company and Ms. Mooney. Subject to her election by the Shareholders at the 2026 AGM, Ms. Mooney will be entitled to an annual cash compensation of US\$65,000 for her service as a Director and additional cash compensation for serving on any committees of the Board in accordance with the Policy. Additionally, Ms. Mooney will be entitled to future cash compensation and annual equity grants in accordance with the Policy and the 2016 Plan.

We believe Ms. Mooney's extensive experience in finance and knowledge of board governance qualifies her to serve on the Board.

**Dr. Sawyers**, aged 67, is the chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center since 2006, an investigator for the Howard Hughes Medical Institute since 2008, a professor of Medicine at Weill Cornell Graduate School of Medical Sciences since 2008, and a professor of Cell and Development Biology of Weill Cornell Graduate School of Medical Sciences since 2011. Dr. Sawyers served as a director at Novartis AG, an innovative medicines company listed on the New York Stock Exchange (NYSE: NVS), from March 2013 to March 2025. Dr. Sawyers has been a member of scientific advisory board of the Company. Dr. Sawyers is a member of the National Academy of Medicine and a member of the National Academy of Sciences. Dr. Sawyers received a B.A. degree in History from Princeton University in 1981 and an M.D. from Johns Hopkins University School of Medicines in 1985.

As of the date of this announcement, Dr. Sawyers is interested in 25,302 shares of the Company, representing approximately 0.001% of the issued shares (excluding treasury shares) of the Company.

There will be no service contract between the Company and Dr. Sawyers. Subject to his election by the Shareholders at the 2026 AGM, Dr. Sawyers will be entitled to an annual cash compensation of US\$65,000 for his service as a Director and additional cash compensation for serving on any committees of the Board in accordance with the Policy. Additionally, Dr. Sawyers will be entitled to future cash compensation and annual equity grants in accordance with the Policy and the 2016 Plan.

Dr. Sawyers' service on the scientific advisory board of the Company will terminate upon his election to the Board. We believe Dr. Sawyers is qualified to serve on the Board as he is a highly accomplished expert and leader in cancer research and possesses a deep understanding of both the benefits and accessibility of medicines for patients.